Prof Ramy Ibrahim
Ramy Ibrahim, MD, is a recognized leader of clinical development in immunotherapy. He helped develop some of the first breakthrough treatments in the field during his tenure at Bristol-Myers Squibb and MedImmune/AstraZeneca. Dr. Ibrahim currently serves as chief medical officer at the Parker Institute for Cancer Immunotherapy. As part of his role, he has built clinical trial management capabilities within the Institute that enabled the conduct of multi-center clinical trials across the Parker centers. His team is focused on supporting novel combinations that are science driven and innovative.
At AstraZeneca, Dr. Ibrahim was the vice president of clinical development for Immuno-oncology, leading the team developing multiple immunotherapies. Molecules developed under his leadership included durvalumab (anti-PDL1 antibody) and tremelimumab (anti-CTLA-4 antibody) both with single drug and combination therapies with a focus on registrational studies in multiple indications including lung cancer, bladder cancer and head and neck cancer.
As a member of the Bristol-Myers Squibb Immuno-oncology program, he served on the Yervoy (ipilimumab) clinical team supporting the program from early phase II through multiple global launches of the first FDA-approved immune checkpoint inhibitor. In addition, he played a key role in early development for nivolumab (PD-1), PD-L1 and CD137 antibody.
Throughout his career, Dr. Ibrahim has been involved with global cancer immunotherapy societies such as the Society of Immunotherapy for Cancer (SITC), Ludwig Institute, the Cancer Research Institute and Cancer Immunotherapy Trials Network (CITN). He is a trained medical oncologist, who conducted bench and clinical immunotherapy research at the cancer vaccine branch of the National Cancer Institute in Bethesda, MD.